Narrow search
Showing 1 - 10 of 23,973
Cover Image
Drug Development - Stuck in a State of Puberty? : Regulatory Reform of Human Clinical Research to Raise Responsiveness to the Reality of Human Variability
Malinowski, Michael J. - 2012
about the sufficiency of FDA *364 regulation. This Article questions how prescription medicines reach the market and …
Persistent link: https://www.econbiz.de/10013098116
Cover Image
Pharmaceutical Lemons : Innovation and Regulation in the Drug Industry
Katz, Ariel - 2013
been advocated. This paper challenges the central argument in the debate on the topic, namely that drug regulation and drug … innovation are necessarily at odds with each other. Although intuitively appealing, the argument that drug regulation negatively … affects the incentives to innovate does not fully capture the role that regulation plays in this industry. This paper shows …
Persistent link: https://www.econbiz.de/10012754003
Cover Image
The impact of R&D cooperations on drug variety offered on the market : evidence from the pharmaceutical industry
Banerjee, Tannista; Siebert, Ralph - 2014
Our study puts special attention to the fact that R&D cooperations in the pharmaceutical industry are formed at different stages throughout the drug development process. We study if the timing to engage in R&D cooperations in the pharmaceutical industry has different impacts on the technology...
Persistent link: https://www.econbiz.de/10010229875
Cover Image
Private and social returns to R&D : drug development and demographics
Benmelech, Efraim; Eberly, Janice C.; Papanikolaou, Dimitris - 2021
Persistent link: https://www.econbiz.de/10012511903
Cover Image
Biomed Europa: after the coronavirus, a public infrastructure to overcome the pharmaceutical oligopoly
Florio, Massimo - 2020
Persistent link: https://www.econbiz.de/10012242700
Cover Image
The impact of the entry of biosimilars : evidence from Europe
Scott Morton, Fiona; Stern, Ariel D.; Stern, Scott - 2017
Persistent link: https://www.econbiz.de/10011708133
Cover Image
Many are called, few are chosen: the role of science in drug development decisions
Colen, Linde; Belderbos, René; Kelchtermans, Stijn; … - 2022
Persistent link: https://www.econbiz.de/10013541933
Cover Image
Industrial and organizational mutations in the medical and pharmaceutical sectors impulsed by open innovation during the pandemic
Adatto, Laurent; Aouinait, Camille; Son Thi Kim Le; … - In: Proceedings of the ENTRENOVA - ENTerprise REsearch … 8 (2022) 1, pp. 421-434
The Covid-19 pandemic tragically emphasized severe failures of health systems. In particular, the saturation of hospital infrastructures and the lack of medical devices is crucial for respiratory ventilators. The medical and pharmaceutical sectors had to find urgently new ways to innovate...
Persistent link: https://www.econbiz.de/10014308369
Cover Image
Private versus social incentives for pharmaceutical innovation
González, Paula; Macho-Stadler, Inés; … - 2015
We provide a theoretical framework to contribute to the current debate regarding the tendency of pharmaceutical companies to direct their R&D toward marketing products that are "follow-on" drugs of already existing drugs, rather than toward the development of breakthrough drugs. We construct a...
Persistent link: https://www.econbiz.de/10011406575
Cover Image
Evaluating the US pharmaceutical patent policy
Izhak, Olena; Saxell, Tanja; Takalo, Tuomas - 2021
The debate on whether COVID-19 vaccine patents are slowing down the pace of vaccination and the recovery from the crisis has brought the optimal design of pharmaceutical patent policy to the fore. In this paper we evaluate patent policy in the US pharmaceutical industry. We estimate the effect...
Persistent link: https://www.econbiz.de/10012802183